200 related articles for article (PubMed ID: 17949899)
1. Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM).
Nasreen N; Mohammed KA; Lai Y; Antony VB
Cancer Lett; 2007 Dec; 258(2):215-22. PubMed ID: 17949899
[TBL] [Abstract][Full Text] [Related]
2. EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene.
Khodayari N; Mohammed KA; Goldberg EP; Nasreen N
Cancer Gene Ther; 2011 Nov; 18(11):806-16. PubMed ID: 21869823
[TBL] [Abstract][Full Text] [Related]
3. EphA2 as a novel molecular marker and target in glioblastoma multiforme.
Wykosky J; Gibo DM; Stanton C; Debinski W
Mol Cancer Res; 2005 Oct; 3(10):541-51. PubMed ID: 16254188
[TBL] [Abstract][Full Text] [Related]
4. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1.
Noblitt LW; Bangari DS; Shukla S; Knapp DW; Mohammed S; Kinch MS; Mittal SK
Cancer Gene Ther; 2004 Nov; 11(11):757-66. PubMed ID: 15359289
[TBL] [Abstract][Full Text] [Related]
5. Cell adhesion and EGFR activation regulate EphA2 expression in cancer.
Larsen AB; Stockhausen MT; Poulsen HS
Cell Signal; 2010 Apr; 22(4):636-44. PubMed ID: 19948216
[TBL] [Abstract][Full Text] [Related]
6. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin.
Guo H; Miao H; Gerber L; Singh J; Denning MF; Gilliam AC; Wang B
Cancer Res; 2006 Jul; 66(14):7050-8. PubMed ID: 16849550
[TBL] [Abstract][Full Text] [Related]
7. Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells.
Nasreen N; Mohammed KA; Antony VB
Cancer; 2006 Nov; 107(10):2425-35. PubMed ID: 17041885
[TBL] [Abstract][Full Text] [Related]
8. Ligand targeting of EphA2 enhances keratinocyte adhesion and differentiation via desmoglein 1.
Lin S; Gordon K; Kaplan N; Getsios S
Mol Biol Cell; 2010 Nov; 21(22):3902-14. PubMed ID: 20861311
[TBL] [Abstract][Full Text] [Related]
9. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation.
Brantley-Sieders DM; Caughron J; Hicks D; Pozzi A; Ruiz JC; Chen J
J Cell Sci; 2004 Apr; 117(Pt 10):2037-49. PubMed ID: 15054110
[TBL] [Abstract][Full Text] [Related]
10. Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade.
Pratt RL; Kinch MS
Oncogene; 2002 Oct; 21(50):7690-9. PubMed ID: 12400011
[TBL] [Abstract][Full Text] [Related]
11. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder.
Abraham S; Knapp DW; Cheng L; Snyder PW; Mittal SK; Bangari DS; Kinch M; Wu L; Dhariwal J; Mohammed SI
Clin Cancer Res; 2006 Jan; 12(2):353-60. PubMed ID: 16428472
[TBL] [Abstract][Full Text] [Related]
12. Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy.
Noblitt LW; Bangari DS; Shukla S; Mohammed S; Mittal SK
Cancer Gene Ther; 2005 Jan; 12(1):46-53. PubMed ID: 15486559
[TBL] [Abstract][Full Text] [Related]
13. A conditional feedback loop regulates Ras activity through EphA2.
Macrae M; Neve RM; Rodriguez-Viciana P; Haqq C; Yeh J; Chen C; Gray JW; McCormick F
Cancer Cell; 2005 Aug; 8(2):111-8. PubMed ID: 16098464
[TBL] [Abstract][Full Text] [Related]
14. Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene.
Sukka-Ganesh B; Mohammed KA; Kaye F; Goldberg EP; Nasreen N
BMC Cancer; 2012 Jul; 12():309. PubMed ID: 22824143
[TBL] [Abstract][Full Text] [Related]
15. Ephrin-A1 is a negative regulator in glioma through down-regulation of EphA2 and FAK.
Liu DP; Wang Y; Koeffler HP; Xie D
Int J Oncol; 2007 Apr; 30(4):865-71. PubMed ID: 17332925
[TBL] [Abstract][Full Text] [Related]
16. EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model.
Tandon M; Vemula SV; Sharma A; Ahi YS; Mittal S; Bangari DS; Mittal SK
J Gene Med; 2012 Feb; 14(2):77-89. PubMed ID: 22228563
[TBL] [Abstract][Full Text] [Related]
17. [Expression of EphA2 and EphrinA1 in human renal cell carcinoma and its relationship with angiogenesis].
Xu JS; Zhang JX; Geng TH; Wang YF; Wang XL; Zuo LF
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):438-41. PubMed ID: 19950554
[TBL] [Abstract][Full Text] [Related]
18. EphrinA1 repulsive response is regulated by an EphA2 tyrosine phosphatase.
Parri M; Buricchi F; Taddei ML; Giannoni E; Raugei G; Ramponi G; Chiarugi P
J Biol Chem; 2005 Oct; 280(40):34008-18. PubMed ID: 16051609
[TBL] [Abstract][Full Text] [Related]
19. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor.
Wykosky J; Palma E; Gibo DM; Ringler S; Turner CP; Debinski W
Oncogene; 2008 Dec; 27(58):7260-73. PubMed ID: 18794797
[TBL] [Abstract][Full Text] [Related]
20. Ligand binding up-regulates EphA2 messenger RNA through the mitogen-activated protein/extracellular signal-regulated kinase pathway.
Pratt RL; Kinch MS
Mol Cancer Res; 2003 Dec; 1(14):1070-6. PubMed ID: 14707290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
